Delta Asset Management LLC TN Has $2.60 Million Stake in Pfizer Inc. (NYSE:PFE)

Delta Asset Management LLC TN raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 15.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 97,994 shares of the biopharmaceutical company’s stock after acquiring an additional 13,361 shares during the quarter. Delta Asset Management LLC TN’s holdings in Pfizer were worth $2,600,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in PFE. Charles Schwab Investment Management Inc. increased its holdings in shares of Pfizer by 19.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock worth $4,124,330,000 after buying an additional 25,315,159 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Pfizer during the 4th quarter valued at $274,694,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Pfizer by 22.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company’s stock valued at $1,101,713,000 after purchasing an additional 6,977,587 shares during the last quarter. Fisher Asset Management LLC boosted its stake in Pfizer by 79.5% in the fourth quarter. Fisher Asset Management LLC now owns 11,148,116 shares of the biopharmaceutical company’s stock worth $295,760,000 after purchasing an additional 4,938,209 shares in the last quarter. Finally, Van ECK Associates Corp grew its holdings in shares of Pfizer by 28.5% during the fourth quarter. Van ECK Associates Corp now owns 21,286,805 shares of the biopharmaceutical company’s stock worth $564,739,000 after purchasing an additional 4,726,549 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.06% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the subject of a number of research analyst reports. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Citigroup reduced their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Bank of America reissued a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Finally, UBS Group lowered their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, Pfizer currently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Price Performance

Shares of PFE stock opened at $25.19 on Thursday. The firm has a market capitalization of $142.88 billion, a price-to-earnings ratio of 17.87, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a fifty day moving average of $26.12 and a 200-day moving average of $26.98.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same period in the prior year, the company earned $0.10 earnings per share. The company’s revenue for the quarter was up 24.7% compared to the same quarter last year. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.